Ponesimod (Ponvory) for multiple sclerosis
- PMID: 34550110
Ponesimod (Ponvory) for multiple sclerosis
Keywords: Aubagio; COVID-19; Copaxone; Gilenya; Lemtrada; Mayzent; Ponvory; Rebif; Tecfidera; Tysabri; Zeposia; adverse effects; alemtuzumab; dimethyl fumarate; dosage; drug interactions; efficacy; fingolimod; glatiramer acetate; interferon beta; lactation; multiple sclerosis; natalizumab; ofatumumab; ozanimod; ponesimod; pregnancy; safety; siponimod; teriflunomide.
Similar articles
-
Ublituximab (Briumvi) for relapsing multiple sclerosis.Med Lett Drugs Ther. 2023 Mar 6;65(1671):36-38. doi: 10.58347/tml.2023.1671c. Med Lett Drugs Ther. 2023. PMID: 36877282 No abstract available.
-
Drugs for multiple sclerosis.Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-48. Med Lett Drugs Ther. 2021. PMID: 33976089 Review. No abstract available.
-
Ozanimod (Zeposia) for multiple sclerosis.Med Lett Drugs Ther. 2020 Aug 24;62(1605):132-134. Med Lett Drugs Ther. 2020. PMID: 32970043 Review. No abstract available.
-
Multiple Sclerosis Agents.2022 Sep 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2022 Sep 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643690 Free Books & Documents. Review.
-
Cladribine (Mavenclad) for multiple sclerosis.Med Lett Drugs Ther. 2019 Jul 29;61(1577):118-120. Med Lett Drugs Ther. 2019. PMID: 31381552 Review. No abstract available.
Cited by
-
Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod.Front Pharmacol. 2022 Feb 16;13:807639. doi: 10.3389/fphar.2022.807639. eCollection 2022. Front Pharmacol. 2022. PMID: 35250559 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical